Company profile
Lifeline Biotechnologies, Inc.
OTC: LLBO · Healthcare · Medical - Specialties
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH 46DQ —GM —SS 65
v0.1 · 35/100 weight · pillars only
↑ listing tenure, return on assets · ↓ return on equity, balance-sheet leverage
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$58.3k
Employees
—
as of 2026-08-02
Market cap
$2.2M
as of 2026-08-02
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$58.3k-$58.3k2025
Operating income-$58.3k-$58.3k2025
Total assets$441.0k$441.0k2018
Liabilities$385.8k$385.8k2018
Equity$55.2k$55.2k2018
Revenue trend
FY2015 – FY2025 · USD
FY15
FY16
FY17
FY18
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Lifeline Biotechnologies, Inc.’s revenue?
Lifeline Biotechnologies, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
BioVaxys Technology Corp.——VitaSpring Biomedical Co. Ltd.18DPsyence Group Inc.——Nu-Med Plus, Inc.23DGenprex, Inc.34DiMD Companies, Inc.47DNeighbors
Washoe →Key facts
CEOCaren Currier
SectorHealthcare
IndustryMedical - Specialties
HeadquartersReno, NV
ExchangeOTC: LLBO
Employees—
IPO date1995-02-01
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.